Copyright
©The Author(s) 2021.
World J Stem Cells. May 26, 2021; 13(5): 470-484
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.470
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.470
Table 3 Administration schedule
| Rounds | Route | WJ-MSC |
| Round 1 | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 2 (2nd week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 3 (4th week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL | |
| Round 4 (6th week) | IT | 1 × 106/kg in 3 mL |
| IV | 1 × 106/kg in 30 mL | |
| IM | 1 × 106/kg in 20 mL |
- Citation: Kabatas S, Civelek E, Savrunlu EC, Kaplan N, Boyalı O, Diren F, Can H, Genç A, Akkoç T, Karaöz E. Feasibility of allogeneic mesenchymal stem cells in pediatric hypoxic-ischemic encephalopathy: Phase I study. World J Stem Cells 2021; 13(5): 470-484
- URL: https://www.wjgnet.com/1948-0210/full/v13/i5/470.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i5.470